Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $1.14 trillion. The enterprise value is $1.19 trillion.
| Market Cap | 1.14T |
| Enterprise Value | 1.19T |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Share Statistics
Eli Lilly has 891.36 million shares outstanding. The number of shares has decreased by -0.62% in one year.
| Current Share Class | 891.36M |
| Shares Outstanding | 891.36M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 89.40% |
| Float | 888.95M |
Valuation Ratios
The trailing PE ratio is 42.98 and the forward PE ratio is 31.39. Eli Lilly's PEG ratio is 1.48.
| PE Ratio | 42.98 |
| Forward PE | 31.39 |
| PS Ratio | 14.33 |
| Forward PS | 12.36 |
| PB Ratio | 33.69 |
| P/TBV Ratio | 164.92 |
| P/FCF Ratio | 62.74 |
| P/OCF Ratio | 40.64 |
| PEG Ratio | 1.48 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.45, with an EV/FCF ratio of 65.22.
| EV / Earnings | 44.42 |
| EV / Sales | 14.89 |
| EV / EBITDA | 28.45 |
| EV / EBIT | 29.95 |
| EV / FCF | 65.22 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 1.62.
| Current Ratio | 1.35 |
| Quick Ratio | 0.68 |
| Debt / Equity | 1.62 |
| Debt / EBITDA | 1.31 |
| Debt / FCF | 3.02 |
| Interest Coverage | 215.26 |
Financial Efficiency
Return on equity (ROE) is 102.29% and return on invested capital (ROIC) is 42.24%.
| Return on Equity (ROE) | 102.29% |
| Return on Assets (ROA) | 20.36% |
| Return on Invested Capital (ROIC) | 42.24% |
| Return on Capital Employed (ROCE) | 41.89% |
| Weighted Average Cost of Capital (WACC) | 6.72% |
| Revenue Per Employee | $1.59M |
| Profits Per Employee | $534,220 |
| Employee Count | 50,000 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.95 |
Taxes
In the past 12 months, Eli Lilly has paid $6.88 billion in taxes.
| Income Tax | 6.88B |
| Effective Tax Rate | 20.49% |
Stock Price Statistics
The stock price has increased by +83.42% in the last 52 weeks. The beta is 0.51, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +83.42% |
| 50-Day Moving Average | 1,175.21 |
| 200-Day Moving Average | 1,049.28 |
| Relative Strength Index (RSI) | 64.94 |
| Average Volume (20 Days) | 2,770,498 |
Short Selling Information
The latest short interest is 9.12 million, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 9.12M |
| Short Previous Month | 9.35M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.03% |
| Short Ratio (days to cover) | 3.69 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $79.67 billion and earned $26.71 billion in profits. Earnings per share was $29.79.
| Revenue | 79.67B |
| Gross Profit | 66.44B |
| Operating Income | 39.61B |
| Pretax Income | 33.60B |
| Net Income | 26.71B |
| EBITDA | 41.71B |
| EBIT | 39.61B |
| Earnings Per Share (EPS) | $29.79 |
Balance Sheet
The company has $8.95 billion in cash and $54.91 billion in debt, with a net cash position of -$45.16 billion or -$50.67 per share.
| Cash & Cash Equivalents | 8.95B |
| Total Debt | 54.91B |
| Net Cash | -45.16B |
| Net Cash Per Share | -$50.67 |
| Equity (Book Value) | 33.88B |
| Book Value Per Share | 38.00 |
| Working Capital | 16.93B |
Cash Flow
In the last 12 months, operating cash flow was $28.08 billion and capital expenditures -$9.89 billion, giving a free cash flow of $18.19 billion.
| Operating Cash Flow | 28.08B |
| Capital Expenditures | -9.89B |
| Depreciation & Amortization | 2.10B |
| Net Borrowing | 15.22B |
| Free Cash Flow | 18.19B |
| FCF Per Share | $20.41 |
Margins
Gross margin is 83.40%, with operating and profit margins of 49.72% and 33.53%.
| Gross Margin | 83.40% |
| Operating Margin | 49.72% |
| Pretax Margin | 42.17% |
| Profit Margin | 33.53% |
| EBITDA Margin | 52.35% |
| EBIT Margin | 49.72% |
| FCF Margin | 22.83% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | 15.34% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 22.46% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 1.19% |
| Earnings Yield | 2.34% |
| FCF Yield | 1.59% |
Analyst Forecast
The average price target for Eli Lilly is $1,310.90, which is 2.39% higher than the current price. The consensus rating is "Buy".
| Price Target | $1,310.90 |
| Price Target Difference | 2.39% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | 20.32% |
| EPS Growth Forecast (3Y) | 30.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 6.55 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.55 |
| Piotroski F-Score | 7 |